Iantech, Inc., a US-based developer of a cataract treatment device, raised a venture capital funding round of undisclosed amount.
Backers included The Global Health Investment Fund (GHIF) and Visionary Venture Fund.
The company will use the funding to further R&D and commercial efforts for its miLOOP technology.
Co-founded by ophthalmic surgeon-innovator Dr. Sean Ianchulev and Luke Clauson, COO, and led by Brian Walsh, CEO, Iantech provides miLOOP, a major advancement in cataract surgery, allowing energy-free lens fragmentation through a minimally invasive clear cornea incision. miLOOP is a pen-like device that utilizes nitinol micro-filament technology to fragment the lens for removal through a micro-incision without using any energy.
The device is now commercially available in select US markets and can be used with industry-standard phacoemulsification techniques, allowing surgeons to manage challenging cataract cases, address a wider range of cases, and improve outcomes for cataract patients.